MyFinsight
Home
Compare
Blog
About
Latigo Biotherapeutics, Inc. (LTGO)
Latigo Biotherapeutics, Inc. (LTGO)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Change in Cash
-$14,511K
Free Cash flow
-$48,460K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of conver...
Stock-based compensation expense
Accrued expenses and other curre...
Others
Negative Cash Flow Breakdown
Other assets
Accounts payable
Payment of deferred initial publ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
Net loss
-48,758
Non-cash lease expense
281
Depreciation
99
Stock-based compensation expense
4,121
Change in fair value of preferred stock tranche liability
0
Amortization of debt discount and issuance costs
275
Prepaid expenses and other current assets
-198
Other assets
3,262
Accounts payable
-1,449
Accrued expenses and other current liabilities
441
Operating lease liabilities
-296
Net cash used in operating activities
-48,350
Purchases of property and equipment
110
Net cash used in investing activities
-110
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs paid
0
Proceeds from issuance of convertible notes
35,000
Proceeds from issuance of common stock upon exercise of stock options
231
Payment of deferred initial public offering costs
1,282
Net cash provided by financing activities
33,949
Net (decrease) increase in cash, cash equivalents and restricted cash
-14,511
Cash, cash equivalents and restricted cash, beginning of period
69,721
Cash, cash equivalents and restricted cash, end of period
55,210
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
convertible notes
$35,000K
Proceeds from issuance of
common stock upon...
$231K
Net cash provided by
financing activities
$33,949K
Canceled cashflow
$1,282K
Net (decrease)
increase in cash, cash...
-$14,511K
Canceled cashflow
$33,949K
Stock-based compensation
expense
$4,121K
Accrued expenses and
other current...
$441K
Non-cash lease expense
$281K
Amortization of debt discount
and issuance costs
$275K
Prepaid expenses and
other current assets
-$198K
Depreciation
$99K
Payment of deferred
initial public offering...
$1,282K
Net cash used in
operating activities
-$48,350K
Canceled cashflow
$5,415K
Net cash used in
investing activities
-$110K
Net loss
-$48,758K
Other assets
$3,262K
Accounts payable
-$1,449K
Operating lease
liabilities
-$296K
Purchases of property and
equipment
$110K
Buy us a coffee